GU Cancers Symposium 2014 - 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase III ALSYMPCA study - Poster

SAN FRANCISCO, CA USA (UroToday.com) - Presented by S. Nilsson,1 N. Vogelzang,2 O. Sartor,3 D. Bottomley,4 R. Coleman,5 I. Skjorestad,6 M. Wahba,7 and C. Parker8 at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Nilsson ASCOGU 2014 thumb

1Karolinska University Hospital, Stockholm, Sweden; 2Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 3Tulane Cancer Center, New Orleans, LA, USA; 4St. James Hospital, Leeds, UK; 5Weston Park Hospital, Sheffield, UK; 6Algeta ASA, Oslo, Norway; 7Bayer HealthCare, Whippany, NJ, USA; 8The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK 

Click HERE to read an exclusive report by a UroToday medical writer

Click HERE to listen to an exclusive interview with one of the authors of this study

View Full 2014 GU Cancers Symposium Coverage 

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland